Literature DB >> 34370572

Imipenem-Relebactam Susceptibility and Genotypic Characteristics of Carbapenem-Resistant Enterobacterales Identified during Population-Based Surveillance.

Sam Horwich-Scholefield1, Tyler Lloyd2, Vici Varghese2, Emily Yette1, Sandra Huang1, Mark Pandori3.   

Abstract

Laboratories submit all carbapenem-resistant Enterobacter, Escherichia coli, and Klebsiella species to the Alameda County Public Health Department (ACPHD). ACPHD evaluated 75 isolates submitted during 9 months for susceptibility to imipenem-relebactam (I-R) and, using whole-genome sequencing, identified β-lactamase genes. Of 60 (80%) isolates susceptible to I-R, 8 (13%) had detectable carbapenemase genes, including 4 KPC, two NDM, and two OXA-48-like; we described the relationship between the presence of β-lactamase resistance genes and susceptibility to I-R.

Entities:  

Keywords:  NDM; carbapenem resistance; imipenem-relebactam; whole-genome sequencing; β-lactamase inhibitor

Mesh:

Substances:

Year:  2021        PMID: 34370572      PMCID: PMC8522770          DOI: 10.1128/AAC.02288-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.

Authors:  Lucía Fernández; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

3.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.

Authors:  Ryan K Shields; Liang Chen; Shaoji Cheng; Kalyan D Chavda; Ellen G Press; Avin Snyder; Ruchi Pandey; Yohei Doi; Barry N Kreiswirth; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

4.  Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.

Authors:  Amabel Lapuebla; Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

5.  In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.

Authors:  Suzannah M Schmidt-Malan; Avisya J Mishra; Ammara Mushtaq; Cassandra L Brinkman; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate In Vitro Susceptibility to Imipenem-Relebactam in Diverse Enterobacteriaceae.

Authors:  Angela Gomez-Simmonds; Stephania Stump; Marla J Giddins; Medini K Annavajhala; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae.

Authors:  Nora Chea; Sandra N Bulens; Thiphasone Kongphet-Tran; Ruth Lynfield; Kristin M Shaw; Paula Snippes Vagnone; Marion A Kainer; Daniel B Muleta; Lucy Wilson; Elisabeth Vaeth; Ghinwa Dumyati; Cathleen Concannon; Erin C Phipps; Karissa Culbreath; Sarah J Janelle; Wendy M Bamberg; Alice Y Guh; Brandi Limbago; Alexander J Kallen
Journal:  Emerg Infect Dis       Date:  2015-09       Impact factor: 6.883

8.  Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa.

Authors:  Ashika Singh-Moodley; Olga Perovic
Journal:  BMC Infect Dis       Date:  2016-10-04       Impact factor: 3.090

9.  Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.

Authors:  Dongxu Sun; Debora Rubio-Aparicio; Kirk Nelson; Michael N Dudley; Olga Lomovskaya
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Authors:  Johann Motsch; Cláudia Murta de Oliveira; Viktor Stus; Iftihar Köksal; Olexiy Lyulko; Helen W Boucher; Keith S Kaye; Thomas M File; Michelle L Brown; Ireen Khan; Jiejun Du; Hee-Koung Joeng; Robert W Tipping; Angela Aggrey; Katherine Young; Nicholas A Kartsonis; Joan R Butterton; Amanda Paschke
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.